Skip to main content

Applications Open for 2021 CSL Centenary Fellowships

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.

news

Australia’s best and brightest biomedical researchers are invited to apply for one of two CSL Centenary Fellowships worth $1.25 million over five years in support of discovery and translational medical research.

Applications are now open for the 2021 Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.

In 2016, in celebration of the company’s 100 year anniversary, CSL established a flagship $25 million fellowship program to champion excellence in early stage translational research.

As well as paying tribute to CSL’s origins, the fellowships aim to foster a thriving medical research community by supporting the development of Australian science.

“Australia is home to CSL’s global hub for early research and translation medicine and we are committed to helping grow the quality and quantity of Australian research and our biotech ecosystem generally,” said Professor Andrew Cuthbertson AO, CSL’s Chief Scientific Officer.

“These fellowships are long term, high value, and mid-career. I am confident that the recipients of the CSL Centenary Fellowships will go on to become some of Australia’s most eminent scientists and will lead the next generation of Australian scientific endeavour” said Professor Cuthbertson.

There are now eight active CSL Fellows working at the QIMR Berghofer Institute, the Queensland Brain Institute, the Peter MacCallum Cancer Centre, Baker Heart and Diabetes Institute, Monash University, Murdoch Children’s Research Institute, Menzies School of Health Research and the South Australian Health and Medical Research Institute. Their research includes work on curing ‘hidden’ malaria, personalised cancer treatment, improving survival rates for patients with acute leukaemia, whether memories are stored in our DNA, liquid biopsies for cancer testing, what really causes arteries to clog, why people die from infection following stroke and vaccines against diseases such as tuberculosis.

The winners of the 2021 CSL Centenary Fellowships will be announced on 11th October 2021 in conjunction with the annual conference of the Australian Academy of Health and Medical Sciences.  

For more information, including application details, visit: www.cslfellowships.com.au

About CSL

CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 70 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSL

Media Contact

Christina Hickie, CSL LimitedPhone: +61 9389 3425/ 0429 609 762